Seqens Supports EU Anti-Dumping Probe into Chinese Acetylsalicylic Acid Imports

admin — Mon, 05 Oct 2026 00:00:00 +0000

The European Commission has initiated an anti-dumping investigation into imports of acetylsalicylic acid (ASA) originating in China. SEQENS says it supports open trade and fair competition on a level playing field, and it will fully cooperate with the Commission throughout the process. The company describes ASA as a critical pharmaceutical ingredient used in Aspirin and other essential healthcare applications, and it has long prioritised a competitive European manufacturing base for key active pharmaceutical ingredients.

Why it matters

The probe could reshape European ASA sourcing and pricing, affecting Chinese import competition and the supply of Aspirin and other healthcare products that depend on this ingredient.

Key facts

Companies	SEQENS, European Commission
Chemicals	acetylsalicylic acid (ASA)
Timing	05/10/2026
Partners	European Commission
End uses	Aspirin, healthcare applications, critical medicines

Market context

Acetylsalicylic acid, better known as aspirin's active ingredient, is a widely used active pharmaceutical ingredient for pain relief, fever reduction, and cardiovascular preventive therapy. Demand is driven mainly by generic and over-the-counter medicine manufacturers and by public healthcare systems that buy large volumes of low-cost essential medicines, so pricing tends to be sensitive to import competition. When an authority opens an anti-dumping investigation, buyers typically watch for changes in import volumes, possible duties on the origin country, and shifts in how contracts are sourced between Asian producers and European manufacturers. Such probes can take months to conclude, and outcomes often depend on evidence about pricing and injury to domestic producers. In the meantime, importers and formulators may diversify suppliers or hold extra inventory, which can tighten availability and affect quoted prices for ASA across the European market.

Source: official release on seqens.com. Summary and context written by Market Krystal.

The post Seqens Supports EU Anti-Dumping Probe into Chinese Acetylsalicylic Acid Imports appeared first on Market Krystal.

SEQENS Completes Transfer of Wavelength Activities to New Shareholder

admin — Tue, 01 Sep 2026 00:00:00 +0000

SEQENS has completed the transfer of its Wavelength activities, including Wavelength Enterprises Ltd. in Israel, Wavelength Enterprises Inc. in the United States and Monolom India Pharma Private Limited in India, to a new shareholder. Wavelength, which joined the group in 2021, develops and manufactures generic active pharmaceutical ingredients and complex chemistry from its Petah Tikva headquarters and Neot Hovav manufacturing site in Israel. Monolom provides research and development support from Pune, India, and the business now operates under local ownership.

Why it matters

Pharmaceutical API supply from the Neot Hovav site and related Israeli, US and Indian operations moves under new ownership, which could shift sourcing and capacity decisions for generic API customers.

Key facts

Companies	SEQENS, Wavelength Enterprises Ltd., Wavelength Enterprises Inc., Monolom India Pharma Private Limited, Wavelength
Chemicals	Active Pharmaceutical Ingredients (APIs)
Location	Petah Tikva and Neot Hovav, Israel; Pune, India
Timing	2021, 2026-08-30
Partners	new shareholder (unnamed)
End uses	pharmaceutical

Market context

Generic active pharmaceutical ingredients are the chemical building blocks that give finished medicines their therapeutic effect, and they are produced in large volumes by specialist contract and generic manufacturers. Demand is driven mainly by the pharmaceutical sector, particularly off-patent drugs where price competition is intense and buyers often qualify several suppliers for the same molecule. Ownership changes at API makers can matter to customers because they may affect quality systems, regulatory filings, capacity allocation and long-term supply commitments, even when day-to-day production continues. Buyers of generic APIs typically respond to such transitions by reviewing supplier qualification and dual-sourcing options. Complex chemistry capabilities, which combine multistep synthesis with process development, are valued because they are harder to replicate than simple commodity intermediates. Research and development support from linked service sites can also influence how quickly new molecules move into commercial production. For investors and procurement teams, the key questions after a transfer like this are usually continuity of operations, site-level compliance and how the new owner plans to allocate capacity across its customer base.

Source: official release on seqens.com. Summary and context written by Market Krystal.

The post SEQENS Completes Transfer of Wavelength Activities to New Shareholder appeared first on Market Krystal.

Seqens Archives | Market Krystal

Seqens Supports EU Anti-Dumping Probe into Chinese Acetylsalicylic Acid Imports

Key facts

Market context

SEQENS Completes Transfer of Wavelength Activities to New Shareholder

Key facts

Market context